54 results about "Vascular endothelial cell proliferation" patented technology

The invention relates to the field of pharmaceutical chemistry, and in particular to a lenalidomide derivative (I). G and n are defined in a direction book. Pharmacological tests show that the lenalidomide derivative plays an inhibiting role in vascular endothelial cell proliferation and can be used for clinical treatment of tumors or chronic inflammations.

The invention discloses a multifunctional fused polypeptide as well as a preparation method and application thereof, belonging to the field of bioengineering pharmaceuticals. The multifunctional fused polypeptide is a combination of one or any multiple of six polypeptides and can be used for preventing and treating solid tumors, rheumatoid arthritis and neovascular eye disease. The multifunctional fused polypeptide is prepared by adopting an artificial synthesis method and is characterized in that angiogenesis is restrained by restraining vascular endothelial cell proliferation and migration, and subsequently the angiogenesis-related diseases, such as solid tumors, rheumatoid arthritis and neovascular eye disease are treated.

The invention relates to functional self-assembling nano peptide hydrogel (RADA16-I / KLT / RGD) which can promote cell adhesion and can promote vascular endothelial cell proliferation and migration. The functional self-assembling nano peptide hydrogel comprises ion complementary type self-assembling nano peptide RADA16-I, KLT function peptide containing VEGF (vascular endothelial growth factor) mimetic peptide fragments and RGD function peptide containing RGD short peptide sequences. The functional self-assembling nano peptide hydrogel can promote cell adhesion, can promote vascular endothelial cell proliferation and migration, is a good tissue engineering framework material, and can be used for scientific research of tissue engineering technology or cytobiology and the like. The invention further provides physical characteristics, a preparation method and an application of the functional self-assembling nano peptide hydrogel.

The invention provides a human anti-vascular endothelial cell growth factor (VEGF) antibody as well as a coding gene and an application thereof. According to the invention, by virtue of genetic engineering means and a phage surface display technology, an anti-VEGF genetic engineering single-chain antibody is screened from a complete synthesis single-chain human antibody library, a variable region gene sequence of the anti-VEGF genetic engineering single-chain antibody is obtained, amino acids in a CDR (complementary determining region) of the anti-VEGF genetic engineering single-chain antibody are transformed by virtue of bioinformatics means, and finally a series of high-affinity anti-VEGF antibodies are obtained by constructing and screening mutation libraries and utilizing a chain exchange method, wherein affinity of the anti-VEGF antibodies with human VEGF is 10<-9>-10<-11>M. According to the invention, identification on immunocompetence and biological activity of the antibody is completed, the anti-VEGF antibody is verified to have the characteristic of being antagonistic to combination of VEGF and VEGFR2 and can effectively inhibit proliferation of vascular endothelial cells induced by VEGF. The invention provides a new specific candidate antibody molecule for resisting tumour and senile macular degeneration targeted by VEGF in future.

It is intended to provide a novel polypeptide having an activity of growing vascular endothelial cells, an activity of promoting transcription form c-fos promoter, an activity of promoting transciption from VEGF promoter and / or an angiogenic activity; a polynucleotide encoding this polypeptide; the above polypeptide and / or a pharmaceutical composition containing the polypeptide for treating a disease selected from the group consisting of obstructive arteriosclerosis, Buerger's disease, peripheral vascular disorder, angina, myocardial infraction, brain infarction, ischemic heart disease and ischemic brain disease; a method of treating these diseases; and an antibacterial composition. The above problems can be solved by isolating a novel peptide having the above-described activities and a nucleotide encoding this peptide.

Disclosed are uses of artemisinin and derivatives thereof in the manufacture of medicaments for inhibition of ocular vascular endothelial cell proliferation, or the prevention and treatment of related diseases of ocular vascular system exudation, edema, new blood vessels formation and proliferation, and pharmaceutical compositions comprising artemisinin and derivatives thereof. Artemisinin and derivatives thereof of the present invention can be used for the prevention and treatment of ocular vascular related diseases, such as age-related macular degeneration, diabetic retinopathy, retinal central vein occlusion and retinal branch vein occlusion etc.

A DNA vaccine effective for inhibiting endothelial cell proliferation comprises a DNA construct operably encoding a vascular endothelial growth factor (VEGF) receptor protein. This invention provides DNA vaccines that encode VEGF receptor-2 (KDR, SEQ ID NO: 2), VEGF receptor-1 (Flt-1, (SEQ ID NO: 4), or Flk-1 (the murine homolog of KDR, SEQ ID NO: 6), DNA sequences SEQ ID NOS: 1, 3, and 5 respectively, as well as methods of using such a DNA vaccine to inhibit vascular endothelial cell proliferation in the tumor micro-environment. Anti-angiogenesis and subsequent decrease in tumor growth and dissemination is achieved.

The invention belongs to the field of antibody drug, and discloses a full human-derived anti-human VEGFR2 monoclonal antibody screened by a phage antibody base technology and prepared by a gene engineering method, and further discloses a carrier including polynucleotide for encoding the monoclonal antibody, a host cell and an application. Through combining with VEGFR2, the monoclonal antibody stops the combination of VEGF with VEGR2, and does not induce receptor dimerization, cause the following tyrosine residue phosphorylation in intracellular tyrosine kinase structure and activate downstream signal access including activation of phospholipase C and increase of calcium ion concentration in the cell and others; the antibody drug triggers endothelial proliferation, survival, cytoskeleton rearrangement, cell migration, gene expression and others, and finally stops the vascular proliferation caused by combination of VEGF and VEGFR2 and induction of dimerization. The monoclonal antibody can be used for treating diseases caused by tumor angiogenesis.

The invention discloses an application of calycosin in radix astragali in preparing a medicament for vascular protection. Angiogenesis is promoted by vascular endothelial cell proliferation, , and further a good vascular protection effect is generated; the prepared medicament used as a selective estrogen modulator can replace estrogen, promote the angiogenesis, and protect the vascular endothelialcells, thereby treating cardiovascular diseases (such as atherogenesis and the like).

[PROBLEMS] To find out a specific rare sugar having effects of inhibiting the proliferation of vascular endothelial cells and lumen formation and utilize these effects. To provide this rare sugar as a preventive / remedy for diseases with angiogenesis, a cosmetic or a functional food.[MEANS FOR SOLVING PROBLEMS] A method of controlling the proliferation of vascular endothelial cells characterized by utilizing the vascular endothelial cell proliferation-controlling effect of D-mannose, D-allose, 2-deoxy-D-glucose, 3-deoxy-D-glucose, L-sorbose, 2-deoxy-D-ribose and / or 2-deoxy-L-ribose. A method of inhibiting lumen formation of vascular endothelial cells characterized by utilizing the vascular endothelial cell lumen formation-inhibiting effect of D-allose, D-altrose, D-gulose, D-talose, L-allose, 2-deoxy-D-glucose, 3-deoxy-D-glucose, D-ribose, L-ribose, 2-deoxy-D-ribose and / or 2-deoxy-L-ribose.

The invention relates to technical field of medicines, and provides a lycopene compound preparation for assisting in treating prostatic cancer and application thereof. The preparation is prepared fromthe following components in parts by weight: 1 to 20 parts of lycopene, 1 to 20 parts of phytosterol or phytosterol ester, 0.1 to 10 parts of selenium-containing compound and 0.1 to 10 parts of zinc-containing compound. The lycopene compound preparation has the effect of restraining tumor cells, can restrain the growth of prostate fibroblasts, restrain the propagation of tumor and vascular endothelial cells and regulate prostate immune cells, and has a propagating effect on intraprostatic immune cell T subgroups. The preparation can regulate the tumor microenvironment, and has the effect of assisting in treating prostate cancer.

The invention discloses an experimental method for promoting tissue engineering pre-vascularization by umbilical cord mesenchymal stem cells; according to the method, vascular endothelial cells and umbilical cord mesenchymal stem cells with different proportions are co-cultured in a two-dimensional manner, and a rule of promoting vascular endothelial cell proliferation and hematopoietic differentiation by the umbilical cord mesenchymal stem cells is studied. In addition, a micron-sized network microvascular scaffold is prepared by high temperature molten monosaccharide and is dissolved in hydrogel to construct a continuous microchannel culture system of a three-dimensional hydrogel female die, the two cells are subjected to perfusion and suspension culture, an in-vitro constructed microvascular network structure and an engineered bone tissue in-vivo transplantation effect based on the structure are evaluated, and a mechanism of the two cells participating and promoting microvascular network construction is illuminated. A new solution and an experimental basis are provided for in-vitro pre-vascularization of engineered tissues and organs.

The invention belongs to the technical field of biomedicine, in particular to the technical field of an albumin medicament. In order to solve the technical problems of short half-life period in vivo and high use level of the existing ATWLPPR peptide, the invention provides an albumin variant. The albumin variant is obtained by mutating a KEQLK peptide section at the tail end of albumin C to a WLPPR peptide section. The albumin variant completely reserves the functions of human albumin and simultaneously has a new ATWLPPR sequence function. Experiments in vitro prove that the albumin variant can obviously inhibit the proliferation and migration of vascular endothelial cells induced by VEGF (Vascular Endothelial Growth Factor) in vitro, and the efficiency of the albumin variant corresponds to that of small peptide. Moreover, when the albumin variant is injected into animals, the efficiency of inhibiting the cornea angiogenesis functions of rabbits is 40-60 times higher than that of the small peptide with the same concentration. The albumin variant can be used as a novel anti-angiogenesis medicament with high efficiency.

The invention discloses a substituted 2,3-dihydro-4(1H)- quinazolone derivative shown in the formula I, pharmaceutically acceptable salt or solvate and a drug composite containing the same and application thereof. The compound has very good effect of restraining vascular endothelial cell proliferation. The compound, the pharmaceutically acceptable salt or solvate or the drug composite containing the same can be used for drugs requiring to restraining angiogenesis diseases and / or cytotoxicity exerting diseases.

The invention discloses application of circRNA in the field of angiogenesis inhibition, and belongs to the fields of biochemistry, molecular biology and medicine. The invention discovers that hsa_circ_0007411 can continuously act on eye vascular endothelial cells, change the structure of angiogenesis and inhibit angiogenesis. By applying the hsa_circ_0007411 to the eye microvascular endothelial cells, 90 percent of angiogenesis can be effectively inhibited, and angiogenesis of neovascularization-related diseases can be effectively inhibited. The effect of hsa_circ_0007411 on cell proliferationand migration is verified, thereby proving that hsa_circ_0007411 can remarkably inhibit cell proliferation and migration, has a remarkable inhibition effect on the proliferation of endothelial cells,and has important guiding significance for diseases related to the proliferation of vascular endothelial cells.

The present invention, preparation process of artificial bone, belongs to biomedicine material technology. The artificial bone can promote vascularization, improve blood circulation, simulate the synergistic action of various osteoplastic factors in body for forming bone well. Technologically, the preparation process of artificial bone includes the steps of preparing cradle, compounding bone forming active factor, sterilizing, assembling and characterized compounding vascular endothelial growth factor. The compounding of bone morphogenitic protein factor, transforming growth factor and vascular endothelial growth factor solves the problem of vascularization and blood supply during the process of forming bone. The vascular endothelial growth factor can promote proliferation and differentiation of vascular endothelial cell and vascularization and raise the capacity of forming bone and vascularization greatly.

The invention belongs to the field of gene engineering, which relates to an Endothelin resistant (esoderma cytostatic agent), its encoding gene and use in preparing medicament for resisting rumor blood vessel production, wherein the esoderma cytostatic agent is screened from No1-89 amino acid fragment of the recombined human collagen IV alpha 2 chain NC1 region, the esoderma cytostatic agent possesses the action of suppressing endocytosis breeding, and can be used in preparing medicament for suppressing blood vessel generation.

An object of the present invention is to provide a chimera VEGF-E having a reduced antigenicity while maintaining the activity of VEGF-E. The present invention provides a chimera protein having an activity of growing vascular endothelial cells, which is obtained by substituting a part of the sequence of a VEGF analogous protein having an activity of vascularization that binds to KDR (VEGF receptor-2) but does not bind to Flt-1 (VEGF receptor-1) with a corresponding sequence of a human-derived VEGF analogous protein.

The invention belongs to the technical field of medicines and particularly relates to a targeting inhibitor for an MCM3AP-AS1 gene and an application of the targeting inhibitor. The targeting inhibitor has the gene sequence as follows: 5'-GCTGTACCTAGTATGGTATGC-3'(SEQ ID No.1). The inhibitor can be specifically bound with the MCM3AP-AS1 gene, so that the MCM3AP-AS1 gene is silenced, influences of MCM3AP-AS1 on vascular endothelial cell proliferation, migration and vessel formation capability of gliomas are inhibited, and the purpose of treating gliomas is achieved.

The invention provides a vascular endothelial growth factor chitosan microsphere. The matrix of the microsphere is chitosan with deacetylation degree of more than or equal to 90.0 percent and viscosity of 100mPa.s, the coated active protein is a vascular endothelial growth factor, and the microsphere has the grain size of 200 to 300 nanometers. The chitosan microsphere serves as a carrier, the vascular endothelial growth factor is coated, and experiments prove that: the chitosan microsphere can well encapsulate and envelop the vascular endothelial growth factor and can well control the release of the vascular endothelial growth factor in a longer time. Moreover, the carrier is not needed to be taken out after administration and can be completely degraded and metabolized in vivo, decomposition products and metabolic products of the carrier are harmless to a human body, and the chitosan microsphere can be applied in preparing medicaments for promoting vascular endothelial cell proliferation and promoting growth of new blood vessels.

A recombinant human vascular endothelial growth factor 121 (r-h VEGF 121) is prepared through amplifying VEGF121 CDMA gene fragment by RT-PCR method, recombining with yeast expression carrier pPIC9K to obtain expression plasmid p9KVEGF121, transforming Pichia eyast GS115, screening efficient expressed engineering strain, fermenting, inducing expression, separation and purifying. It can be used for preventing and treating is chemic diseases.

The invention provides a method for preparing adipose-derived stem cell exosomes, the adipose-derived stem cell exosomes and application thereof and belongs to the technical field of bioengineering. The preparing method comprises the steps: 1, mixing adipose-derived stem cells with an electrotransfection working solution to obtain a mixed solution, and mixing the mixed solution with a CTF1 plasmidto obtain a pre-transfection object; 2, conductng electric shock on a pre-transfection material obtained in the step 1 to obtain adipose stem cells transfected with a CTF1 gene; 3, carrying out conventional culture on the adipose stem cells transfected with the CTF1 gene obtained in the step 2, and collecting the adipose-derived stem cell exosomes. The adipose-derived stem cell exosomes preparedby the method can remarkably promote proliferation of endometrial microvascular endothelial cells.

A DNA composition effective for inhibiting endothelial cell proliferation comprises a DNA construct operably encoding a vascular endothelial growth factor (VEGF) receptor polypeptide, which can be a full length VEGF receptor protein or an immunogenic fragment thereof. This invention provides DNA compositions that encode VEGF receptor-2 (KDR), VEGF receptor-1 (Flt-1), or Flk-1 (the murine homolog of KDR), as well as methods of using such a DNA composition to inhibit vascular endothelial cell proliferation in the tumor micro-environment. Angiogenesis inhibition and subsequent decrease in tumor growth and dissemination is achieved.

The invention relates to the field of medicinal chemistry and particularly relates to a class of N-[1, 3, 6-tri-O-acetyl-4-O-(2, 3, 4, 6-quadri-O-acetyl)-beta-D-galactosyl]-2-deoxy-beta-D-glucosyl group]-3-(substituted phenyl) acrylamide (I), as well as a preparation method and an application thereof in restriction of vascular endothelial cell proliferation and chick embryo chorioallantoic membrane neovascularization.

The invention relates to functional self-assembling nano peptide hydrogel (RADA16-I / KLT / RGD) which can promote cell adhesion and can promote vascular endothelial cell proliferation and migration. The functional self-assembling nano peptide hydrogel comprises ion complementary type self-assembling nano peptide RADA16-I, KLT function peptide containing VEGF (vascular endothelial growth factor) mimetic peptide fragments and RGD function peptide containing RGD short peptide sequences. The functional self-assembling nano peptide hydrogel can promote cell adhesion, can promote vascular endothelial cell proliferation and migration, is a good tissue engineering framework material, and can be used for scientific research of tissue engineering technology or cytobiology and the like. The invention further provides physical characteristics, a preparation method and an application of the functional self-assembling nano peptide hydrogel.

The invention relates to the field of drugs, in particular to polypeptide for activating angiostatin and treating malignant tumors. The sequence of the polypeptide is EALALMYYHSQSLRKTYP and is a brand new sequence. By means of the polypeptide, the angiostatin can be activated out of a body, proliferation of vascular endothelial cells can be suppressed, the tumor-bearing mice survival rate can be increased in an in-vivo test, and the potential new drug development value is achieved.

The invention discloses simulation oligopeptide CPU-510-02 of the vascular endothelial growth factor (VEGF) epitope and an application of the simulation oligopeptide. The amino acid sequence of the simulation oligopeptide CPU-510-02 is PSCVPLM, and the nucleotide sequence of the simulation oligopeptide CPU-510-02 is CCGTCCTGCGTTCCGCTGATG. An in-vitro experiment shows that the simulation oligopeptide has an obvious inhibition effect in a vascular endothelial cell multiplication process and a tumor cell multiplication process; and therefore, the simulation oligopeptide can be used for preparing polypeptide vaccines, tumor vessel growth inhibitors or tumor guide medicines and has great reference signification for diagnosing generation and development of tumors by taking the VEGF acceptor as a target, discussing the development of tumor vessel growth inhibitors by micro-molecule polypeptides and developing and researching tumor guide medicines.

The invention discloses an application of a pro-angiogenic factor PDGFC as a marker for diagnosis and treatment of a hepatopulmonary syndrome. The PDGFC carries out up-regulated expression in HPS blood and can be a molecule related to angiogenesis, and the DGFC also has performance of promoting microvascular endothelial cell proliferation, migration and tubule formation, a lung injury score of anHPS group is obviously improved after a PDGFC antibody is given, a DGFC can be used as a drug for promoting lung angiogenesis, and the antibody specifically combined with the PDGFC can be used as a drug for treating the HPS, and is expected to be used for intervention of clinical HPS patients.

The invention relates to the field of medicines, in particular to polypeptide for activating angiostatin and treating cancers. The sequence of the polypeptide is NYTPANTPFDFHHSLEHG which is brand new, the polypeptide can activate angiostatin and restrain vascular endothelial cell proliferation in vitro, the survival rate of tumor-bearing mice in in-vivo tests is improved, and the polypeptide has potential new drug development value.

The invention provides a VEGF-CRM197 recombinant fusion protein vaccine as well as a preparation method and application thereof. Specifically, the invention provides a VEGF truncated body VEGF1-107 antigen fragment which loses VEGF biological activity but retains immunogenicity, and the VEGF truncated body VEGF1-107 antigen fragment is fused with a diphtheria toxin mutant CRM197 for recombinant expression to form a VEGF recombinant fusion protein. After the VEGF recombinant fusion protein is combined with a liquid adjuvant for use, high-titer and high-antibody generation in mice and rhesus monkeys can be induced, and combination of VEGF-A and a receptor thereof is blocked, so that the promotion effect of VEGF-A on vascular endothelial cell proliferation is inhibited.